Spin out company from University College Cork in 2016 Artugen Therapeutics went on to become Adiso Therapeutics which specialises in developing therapies for patients with chronic and progressive inflammatory diseases. They have seen particular success with identifying a treatment for prevention of recurrent Clostridioides Difficile Infection (CDI), leading them to receive fast track approval from America’s Food and Drug Administration.